Compare Amylx Pharmaceuticals Inc (AMLX) vs Core Scientific Inc (CORZ) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

CORZ trades at $23.49, down 1.05% on the day, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue growth driven by AI colocation, yet missed EPS estimates. Strong analyst support exists with 19 buy ratings and a $34.17 consensus target, indicating 45% upside potential.

Outlook remains optimistic due to strategic pivot to AI infrastructure, though significant risks include persistent losses, high cash burn, and execution challenges in scaling data center operations amid competitive and regulatory pressures.